Advertisement

New Approaches in Cancer Pharmacology: Drug Design and Development

Vol. II

  • Paul Workman
  • Maurizio D’lncalci

Part of the ESO Monographs book series (ESO MONOGRAPHS)

Table of contents

  1. Front Matter
    Pages I-VII
  2. Paul Workman
    Pages 1-4
  3. Kenneth R. Harrap
    Pages 23-37
  4. Paul Workman, Valerie G. Brunton, David J. Robins
    Pages 55-70
  5. Wilfried Bursch
    Pages 71-85

About these proceedings

Introduction

The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

Keywords

Cancer Pharmacology Krebs Pharmakologie Pharmastruktur apoptosis biology cancer cancer therapy clinical trial drug drug design molecular biology pharmacology

Editors and affiliations

  • Paul Workman
    • 1
    • 3
  • Maurizio D’lncalci
    • 2
  1. 1.Cancer Research Campaign Beatson Laboratories, CRC Department of Medical OncologyUniversity of GlasgowBearsden, GlasgowUK
  2. 2.Istituto Mario NegriMilanoItaly
  3. 3.Cancer Research DepartmentZENECA PharmaceuticalsMacclesfield, CheshireUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-79088-1
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-79090-4
  • Online ISBN 978-3-642-79088-1
  • Buy this book on publisher's site